anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Iatrogenic blood losses from repetitive laboratory testing are a leading cause of anemia of prematurity and blood transfusions. We used an implementation science approach to decrease iatrogenic blood losses during the first 3 postnatal weeks among very low birth weight infants.
METHODS: We performed qualitative interviews of key stakeholders to assess implementation determinants (ie, barriers and facilitators to reducing iatrogenic blood losses), guided by the Consolidated Framework for Implementation Research. Next, we selected implementation strategies matched to these implementation determinants to de-implement excess laboratory tests. The number of laboratory tests, amount of blood taken (ml/kg), and laboratory charges were compared before and after implementation using quasi-Poisson and multi-variable regression models.
RESULTS: Qualitative interviews with 14 clinicians revealed implementation-related themes, including provider-specific factors, recurring orders, awareness of blood loss and cost, and balance between over- and under-testing. Implementation strategies deployed included resident education, revised order sets, blood loss and cost awareness, audit and feedback, and the documentation of blood out. There were 184 and 170 infants in the pre- and postimplementation cohorts, respectively. There was an 18.5% reduction in laboratory tests (median 54 [36 - 80] versus 44 [29 - 74], P = .01) in the first 3 postnatal weeks, a 17% decrease in blood taken (mean 18.1 [16.4 - 20.1] versus 15 [13.4 - 16.8], P = .01), and an overall reduction of $290 328 in laboratory charges. No difference was noted in the number of blood transfusions. Postimplementation interviews showed no adverse events attributable to implementation strategies.
CONCLUSIONS: An implementation science approach combining qualitative and quantitative methods reduced laboratory tests, blood loss, and charges.
Monoamine oxidase B (MAO-B) is an enzyme localized to the outer mitochondrial membrane and highly concentrated in astrocytes. Temporal changes in regional MAO-B levels can be used as an index of astrocytic proliferation, known as activated astrocytes or astrogliosis. MAO-B is a marker to evaluate the degree of astrogliosis. Therefore, MAO-B positron emission tomography (PET) is a powerful imaging technique for visualizing and quantifying ongoing astrogliosis through the estimate of regional MAO-B levels. Each neurodegenerative disorder generally has a characteristic distribution pattern of astrogliosis secondary to neuronal loss and pathological protein aggregation. Therefore, by imaging astrogliosis, MAO-B PET can be used as a neurodegeneration marker for identifying degenerative lesions. Any inflammation in the brain usually accompanies astrogliosis starting from an acute phase to a chronic phase. Therefore, by imaging astrogliosis, MAO-B PET can be used as a neuroinflammation marker for identifying inflammatory lesions. MAO-B levels are high in gliomas originating from astrocytes but low in lymphoid tumors. Therefore, MAO-B PET can be used as a brain tumor marker for identifying astrocytic gliomas by imaging MAO-B levels and distinguishing between astrocytic and lymphoid tumors. This review summarizes the clinical application of MAO-B PET using 18F-THK5351 as markers for neurodegeneration, neuroinflammation, and brain tumors in neurological disorders. Because we assume that MAO-B PET is clinically applied to an individual patient, we focus on visual inspection of MAO-B images at the individual patient level. Geriatr Gerontol Int 2024; 24: 31-43.
For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
PURPOSE:To obtain the titled factor useful as an agent to suppress the secretion of gastric juice, in high purity, by contacting a resin adsorent to extracted glandula submandibularis of mouse or its roughly purified product to effect the adsorption of the epitheliocyte growth factor, and eluting the absorbed factor with a mixture of water and a water-soluble organic solvent. CONSTITUTION:Extract of the glandula submandibularis of mouse or its roughly purified product is made to contact with a resin adsorbent, e.g. non-ion-exchanging porous styrene-divinylbenzene resin [commercial name, Amberlite XAD-2 or XAD-4 (products of Rohm & Haas)], to effect the absorption of the epithliocyte growth promoting substance (abbreviated as m-EGF). The adsorbed m-EGF is eluted with a mixture of water and a water-soluble organic solvent (e.g. alcohol, acetone, etc.). The water is preferably acidic aqueous solution. The m-EGF obtained by the present invention is stable to heat and acid, and keeps its activity for >=1 week at room temperature.
The invention provides transgenic non-human animals which exhibit both APP and tau-linked features, e.g. histological features, of AD pathology, and preferably also behavioural changes characteristic of AD. Suitably the transgenic non-human animals express a human APP comprising the Swedish mutation or the Swedish mutation in combination with one or more additional mutations, in particular the London mutation. It appears that the level at which the transgene is expressed in the transgenic animal, e.g. the level of transgene mRNA, is an important factor for obtaining AD pathology in the animal. Transgenic mice expressing said mutated human APP under control of Thy-1 promoter element have been found to develop a pathological phenotype which goes beyond that previously described by Games et al. [Nature 373, 523-527, (1995)], by combining APP and tau-linked features of the AD pathology. Moreover, the mice have been found to present behavioural changes characteristic of AD, which has also never been reported before with transgenic animals.
For purposes of exploratory analyses, blood (whole blood, serum, plasma) and urine samples will be collected pre-IR treatment, 1-month post-implant, 6 month follow-up and 2 years follow-up. Patients will be asked to opt-in on the consent form specifically for the 2-year biopsy, otherwise they have the choice to opt out.
An application server predicts respiratory disease risk, rescue medication usage, exacerbation, and healthcare utilization using trained predictive models. The application server includes model modules and submodel modules, which communicate with a database server, data sources, and client devices. The submodel modules train submodels by determining submodel coefficients based on training data from the database server. The submodel modules further determine statistical analysis data and estimates for medication usage events, healthcare utilization, and other related events. The model modules combine submodels to predict respiratory disease risk, exacerbation, rescue medication usage, healthcare utilization, and other related information. Model outputs are provided to users, including patients, providers, healthcare companies, electronic health record systems, real estate companies and other interested parties.
The purpose of this arm is to provide evidence to support that each lot of manufactured reagents for the Spartan Cube CYP2C19 Test produce the same result. Each participant, over the course of the study at the various sites, will be tested using 3 different lots of manufactured Spartan CYP2C19 Test Kits.
Reduced dyes, such as hydrocyanines, deuterocyanines, and/or other deuterated dyes capable of detecting one or more reactive oxygen species are described herein. The reduced dyes exhibit little or no fluorescence due to the disrupted π conjugation. However, upon reaction with ROS, the reduced dyes are oxidized, regenerating the extended π conjugation and causing a substantial increase in fluorescence intensity. In many case, the oxidized dye is generally membrane impermeable. However, upon reduction, many of the reduced dyes are membrane permeable. Thus, reduced dyes can accumulate in cells and/or tissue to amplify the signal. Once inside the cell or tissue, the reduced dye is reoxidized upon reaction with ROS, and the oxidized dye again becomes membrane impermeable, trapping the dye within the cell. The reduced dyes can be used to image ROS, such as hydroxide radical and superoxide, in serum, cell cultures, tissue explants, and in vivo.
Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA \<50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
A method of predicting a disease or condition of a cornea or an anterior segment of an eye includes inputting input data into an AI model, processing the input data, and generating a set of scores and outputting a prediction. The input data may be representative of a cornea or anterior segment of an eye. Processing the input data may include processing the data through the plurality of convolutional layers, the fully connected layer, and the output layer. Each score of the set of scores may be generated by a corresponding node in the output layer. The output prediction may be related to the cornea or anterior segment of the eye represented by the input data processed through the AI model. The prediction may be determined by at least one score of the set of scores.
<P>PROBLEM TO BE SOLVED: To obtain an agent for promoting the absorption of a mineral, containing a fraction of a yeast cell wall as an active ingredient; to obtain an agent for preventing and/or ameliorating osteoporosis, containing the fraction of the yeast cell wall as an active ingredient; and to obtain a pharmacologically active composition for the osteoporosis, containing the fraction of the yeast cell wall as an active ingredient.  <P>SOLUTION: The agent for promoting the absorption of the mineral contains a cell wall fraction of the yeast cell wall as the active ingredient, which is obtained by subjecting a biomass of the yeast to an alkali treatment, and carrying out water-cleaning, physical pulverization treatment and removal treatment of a soluble biomass components of the treated product. The agent for preventing and/or ameliorating the osteoporosis contains the cell wall fraction of the yeast as the active ingredient obtained by subjecting the biomass of the yeast to the alkali treatment, and carrying out the water-cleaning, the physical pulverization treatment and the removal treatment of the soluble biomass components of the treated product. The active ingredient promotes the absorption of the mineral, and is effective for the increase in bone density, the prevention of the osteoporosis and the amelioration of the symptom. The pharmacologically active composition is safe because of little side effects, provides high dispersibility in water and is used as an easily administered material.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Exercise group will receive ROM exercises, stretching and anterior deltoid re-education exercises described by Levy et al. Subjects will treated at the clinic three times per week for 6 weeks (18 sessions).
Astringent compositions useful as antiperspirants are provided by forming a complex of a magnesium salt and an astringent zirconium compound, particularly zirconium oxy and hydroxy salts, such that the weight ratio of the zirconium content to the magnesium content in the complex expressed as the oxides will be in the range of about 30:1 to 1:1. The preferred amount of magnesium, expressed as the oxide, in an aqueous antiperspirant solution containing an effective amount of the complex will be greater than about 3 weight percent. Preferred compositions include complexes of magnesium-amino acid salts, such as magnesium glycinate, plus zirconyl hydroxy chloride in which the ratio of zirconium to magnesium is about 10:1 to 3:1 and the total content of magnesium plus zirconium is about 5 to 15 weight percent and preferably about 5 to 10 weight percent, both expressed as the oxides. Buffers such as urea, amino acids, salts of amino acids, etc. may also be included in the complexes to maintain a pH of at least about 3 in aqueous solutions of the complex. The various complexes of the invention may be used in conventional antiperspirant forms, including aqueous solutions, aerosol sprays, powder-in-oil aerosol sprays, creams, lotions, cream sticks, etc.
PURPOSE: Our goal was to evaluate if self-administered bladder neuromodulation with transcutaneous tibial nerve stimulation could safely replace overactive bladder medications in people with spinal cord injury.
MATERIALS AND METHODS: We performed a 3-month, randomized, investigator-blinded, tibial nerve stimulation vs sham-control trial in adults with spinal cord injury and neurogenic bladder performing intermittent catheterization and taking overactive bladder medications. The primary outcome was a reduction in bladder medications while maintaining stable bladder symptoms and quality of life based on pre/post Neurogenic Bladder Symptom Score and the Incontinence Quality of Life questionnaire, respectively. Secondary outcomes included changes in pre/post cystometrogram, 2-day voiding diaries, and an anticholinergic medication side effect survey.
RESULTS: Fifty people consented to the study, with 42 completing the trial. No dropouts were due to stimulation issues. All baseline demographics and surveys were comparable at baseline. Cystometrogram parameters were also comparable at baseline, except the stimulation group had a higher proportion of loss of bladder compliance compared to the control group. At the end of the trial, a significantly greater percentage of the tibial nerve stimulation group was able to reduce medications (95% vs 68%), by a 26.2% difference in medication reduction (95% CI 1.17%-51.2%). Function and quality of life surveys and cystometrograms at the end of the trial were alike between groups. Transcutaneous tibial nerve stimulation satisfaction surveys and adherence to protocol were high.
CONCLUSIONS: In people with chronic spinal cord injury performing intermittent catheterization, transcutaneous tibial nerve stimulation can be an option to reduce or replace overactive bladder medications.
UNLABELLED: Clinical Trial Registration No.: NCT03458871.
Limited data is available regarding the effects of various periodontal treatment protocols on GCF t-PA and PAI-1 levels, and the extent to which LLLT in conjunction with NSPT affects these levels in patients with Stage 3-4, Grade C periodontitis is unknown. Therefore, this study measured standard clinical outcomes and GCF t-PA and PAI-1 levels in patients with Stage 3-4 Grade, C periodontitis in order to assess the use of LLLT as an adjunct to standard NSPT.

This split-mouth study was conducted with 15 Stage 3-4, Grade C periodontitis patients and 15 healthy individuals matched for age and sex. Participants were grouped as follows: Periodontitis/NSPT (Sham); Periodontitis/NSPT+LLLT (LLLT); Periodontally Healthy (Control). LLLT was applied following NSPT and again on post-treatment Days 2 and 7. Clinical parameters were recorded at baseline (i.e. before NSPT) and on Day 30. Gingival crevicular fluid (GCF) samples were collected at baseline and during follow-up visits on Days 7, 14 and 30. GCF t-PA and PAI-1 levels were measured with ELISA.
Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers. After systemic administration GTN is transformed to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is effective in 60% of patients. These data show that NO is involved in both initiation and maintenance of migraine attack.

The importance of migraine genes is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
The invention relates to a metformin hydrochloride sustained-release capsule and its preparation method. The metformin hydrochloride sustained-release capsule is prepared by steps of coating a metformin hydrochloride granule sustained-release material and putting into an enteric capsule. In comparison with the prior art, sustained-release granules and enteric capsule filling technology are combined together to prepare the new dosage form of metformin hydrochloride sustained-release (enteric-coated) capsule. As the sustained-release granule coating and enteric capsule filing technology is adopted, metformin hydrochloride will not be disintegrated and will not stimulates gastric mucosa, and adverse reactions such as nausea, stomachache, diarrhoea and the like caused by medication can be avoided. Meanwhile, metformin hydrochloride will not be damaged by gastric juice, and bioavailability of metformin hydrochloride is raised. In addition, the product provided by the invention is also a sustained-release enteric-coated preparation. The medicine can be stably released in a body, effective plasma concentration is maintained for a long time, and toxic and side effect which might be caused by higher plasma concentration within a short time are avoided. The frequency for taking the medicine is reduced, and patient compliance is also raised.
BACKGROUND: We aimed to compare 7 newer immunotherapies and targeted therapies for platinum-resistant relapsed ovarian cancer.
METHODS: We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library electronic databases for phase III trials involving platinum-resistant recurrent ovarian cancer (PRrOC) patients treated with immunotherapy or targeted therapy in combination with chemotherapy. The quality of the included trials was assessed using the GRADE method. The primary outcome of comparison was progression-free survival, and secondary outcomes included overall survival and safety.
RESULTS: This analysis included 7 randomized phase III controlled trials, encompassing 2485 PRrOC patients. Combining bevacizumab plus chemotherapy and lurbinectedin demonstrated statistically significant differences in progression-free survival compared to all other regimens of interest. However, no statistically significant differences were observed in the overall survival. Nivolumab and mirvetuximab exhibited fewer serious adverse events than the other regimens of interest.
CONCLUSIONS: Our findings indicate that bevacizumab combined with chemotherapy and lurbinectedin monotherapy has significant efficacy in patients with PRrOC. For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical preparations with the highly flexible and deformable coating, capable of transporting drugs into the body of warm blood creatures.  <P>SOLUTION: Combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid are used. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. At least two of said three system components are soluble substances, and at least one of which is an active ingredient and preferably a drug. The third component, alternatively, can take the role of a drug. Furthermore, an appropriate method is demonstrated for manufacture and utilization of a carrier. The application also describes new formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on the complex aggregates.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Acute diverticulitis (AD) is associated with relevant morbidity/mortality and is increasing worldwide, thus becoming a major issue for national health systems. AD may be challenging, as clinical relevance varies widely, ranging from asymptomatic picture to life-threatening conditions, with continuously evolving diagnostic tools, classifications, and management. A 33-item-questionnaire was administered to residents and surgeons to analyze the actual clinical practice and to verify the real spread of recent recommendations, also by stratifying surgeons by experience. CT-scan remains the mainstay of AD assessment, including cases presenting with recurrent mild episodes or women of child-bearing age. Outpatient management of mild AD is slowly gaining acceptance. A conservative management is preferred in non-severe cases with extradigestive air or small/non-radiologically drainable abscesses. In severe cases, a laparoscopic approach is preferred, with a non-negligible number of surgeons confident in performing emergency complex procedures. Surgeons are seemingly aware of several options during emergency surgery for AD, since the rate of Hartmann procedures does not exceed 50% in most environments and damage control surgery is spreading in life-threatening cases. Quality of life and history of complicated AD are the main indications for delayed colectomy, which is mostly performed avoiding the proximal vessel ligation, mobilizing the splenic flexure and performing a colorectal anastomosis. ICG is spreading to check anastomotic stumps' vascularization. Differences between the two experience groups were found about the type of investigation to exclude colon cancer (considering the experience only in terms of number of colectomies performed), the size of the peritoneal abscess to be drained, practice of damage control surgery and the attitude towards colovesical fistula.
NEW MATERIAL:A compound expressed by formula I (R is di-lower acyloxyboryl or difluoroboryl). EXAMPLE:Diacetoxy [9,1-(methylimino)methano-7,8-difluoro-5-oxo-5H-thiazolo[3,2- a]quinoline-4-carboxy]borane. USE:An intermediate for producing antimicrobial substances. PREPARATION:A compound expressed by formula TV is reacted with 1,3- dichloroacetone to provide 3-chloro-2-oxopropyl N-(2,3,4-trifluorophenyl) dithiocarbamate expressed by formula V, which is then reacted with hydrogen chloride, etc., to afford a compound expressed by formula VI. The resultant compound expressed by formula VI is subsequently reacted with methylamine to provide a compound expressed by formula VII, which is further reacted with a lower alkyl iodide to afford a compound expressed by formula VIII. The obtained compound expressed by formula VIII is then reacted with a sodium di-lower alkyl malonate to produce a compound expressed by formula IX. The resultant compound expressed by formula IX, together with a condensing agent, is heated and cyclized to provide a compound expressed by formula X, which is subsequently reacted with a tri-lower acyloxyborane.
FIELD: medicine, particularly, therapy and endocrinology; applicable in obesity treatment with the help of pulse hypocalorie diet with reduced content of fat. SUBSTANCE: method provides for use of dietotherapy with alternation of unloading die days with days of unmeasured diet. On unloading days, diet includes protein-carbohydrate mixture DOCTOR-SLIM and small quantity of vegetables and fruits with administration of isolipan by 15 mg once in the second half of day. On nonunloading days, patients follow the recommendations to limit use of fat with food up to 35-40 g a day. Treatment course is 12 weeks. EFFECT: reduced body weight by 12 kg on average, decreased arterial pressure, well endurable by patients with no affection of their working ability and normal everyday life. 2 tbl, 1 ex